MYCN and neuroblastoma: Similarly, in 6-day viability assays, when cells were treated with increasing doses of MLN8237, the combination of ABT-199 and MLN8237 was markedly more effective in MYCN-amplified neuroblastoma cells compared with the MYCN-WT neuroblastoma cells and the RPE-1 cell line (Figures S6E and S6F).